Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients

References

• Mahmoud SH, Shen C. Augmented renal clearance in critical illness: an important consideration in drug dosing. Pharmaceutics. 2017 Sep 16;9(3).
   Google Scholar
• U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER). General clinical pharmacology considerations for pediatric studies for drugs and biological products: guidance for industry draft December 2014. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-clinical-pharmacology-considerations-pediatric-studies-drugs-and-biological-products)
   Google Scholar
• Stockmann C, Constance JE, Roberts JK, et al. Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. Clin Pharmacokinet. 2014;53(5):429–454. May.
   Google Scholar
• Wang B, Wang J, Huang SQ, et al. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab. 2009 Sep;10(7):781–834.
   Google Scholar
• Meletiadis J, Chanock S, Walsh TJ. Human pharmacogenomic variations and their implications for antifungal efficacy. Clin Microbiol Rev. 2006 Oct;19(4):763–787.
   Google Scholar
• Amsden JR, Gubbins PO. Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy. Expert Opin Drug Metab Toxicol. 2017 Nov;13(11): 1135–1146.
   Google Scholar
• Ashbee HR, Gilleece MH. Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. Bone Marrow Transplant. 2012 Jul;47(7): 881–894.
   Google Scholar
• Lonsdale DO, Udy AA, Roberts JA, et al. Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations. J Neurosurg. 2013 Feb;118(2):297–301.
   Google Scholar
• Ancobon (flucytosine) [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2019.
   Google Scholar
• Pasqualotto AC, Howard SJ, Moore CB, et al. Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother. 2007 Apr;59(4):791–793.
   Google Scholar
• Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis. 1992 Dec;15(6): 1003–1018.
   Google Scholar
• Polak A, Scholer HJ. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy. 1975;21(3–4):113–130.
   Google Scholar
• Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987 Aug;83(2):236–242.
   Google Scholar
• Kauffman CA, Frame PT. Bone marrow toxicity associated with 5-fluorocytosine therapy. Antimicrob Agents Chemother. 1977 Feb;11(2): 244–247.
   Google Scholar
• Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014 May;69(5):1162–1176.
   Google Scholar
• Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009 Jan;53(1):24–34.
   Google Scholar
• Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect. 2004 Mar;10(Suppl 1): 1–10.
   Google Scholar
• Chang YL, Yu SJ, Heitman J, et al. New facets of antifungal therapy. Virulence. 2017 Feb 17;8(2):222–236.
   Google Scholar
• Greenblatt HK, Greenblatt DJ. Liver injury associated with ketoconazole: review of the published evidence. J Clin Pharmacol. 2014 Dec;54(12): 1321–1329.
   Google Scholar
• Buil JB, Snelders E, Denardi LB, et al. Trends in azole resistance in Aspergillus fumigatus, the Netherlands, 1994-2016. Emerg Infect Dis. 2019 Jan;25(1):176–178.
   Google Scholar
• Perlin DS, Shor E, Zhao Y. Update on antifungal drug resistance. Curr Clin Microbiol Rep. 2015 Jun 1;2(2): 84–95.
   Google Scholar
• Sporanox (itraconazole capsules) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2019.
   Google Scholar
• Piérard GE, Arrese JE. Piérard-Franchimont C. Itraconazole. Expert Opin Pharmacother. 2000 Jan;1(2):287–304. eng.
   Google Scholar
• Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004 Feb 15;103(4):1527–1533.
   Google Scholar
• Patterson TF, Thompson GR, 3rd, Denning DW. et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Aug 15;63(4):e1–e60. .
   Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1–50.
   Google Scholar
• Boogaerts MA, Verhoef GE, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses. 1989;32(Suppl 1):103–108.
   Google Scholar
• Myers E, Dodds Ashley E. Antifungal drug therapeutic monitoring: what are the issues? Curr Clin Micro Rep. 2015;2:55–66.
   Google Scholar
• Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother. 2005 Sep;56(Suppl 1): i17–i22.
   Google Scholar
• Sporanox (itraconazole oral solution) [package insert] Titusville, NJ: Janssen Pharmaceuticals, Inc; 2019.
   Google Scholar
• Tolsura (itraconazole capsules) [package insert]. Greenville, NC: Mayne Pharma; 2018.
   Google Scholar
• Abuhelwa AY, Foster DJ, Mudge S, et al. Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother. 2015;59(9):5681–5696. Sep.
   Google Scholar
• de Repentigny L, Ratelle J, Leclerc JM, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother. 1998 Feb;42(2):404–408.
   Google Scholar
• Schmitt C, Perel Y, Harousseau JL, et al. Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis. Antimicrob Agents Chemother. 2001 May;45(5):1561–1564.
   Google Scholar
• Groll AH, Wood L, Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 2002 Aug;46(8):2554–2563.
   Google Scholar
• Leong YH, Boast A, Cranswick N, et al. Itraconazole dosing and drug monitoring at a tertiary children’s hospital. Pediatr Infect Dis J. 2019 Jan;38(1):60–64.
   Google Scholar
• Allegra S, Fatiguso G, De Francia S, et al. Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. Clin Exp Pharmacol Physiol. 2017 Nov;44(11):1083–1088.
   Google Scholar
• Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649–663.
   Google Scholar
• Vfend [package insert]. New York, NY: Pfizer Inc; 2003.
   Google Scholar
• Job KM, Olson J, Stockmann C, et al. Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections. Expert Rev Anti Infect Ther. 2016 Aug;14(8):731–746.
   Google Scholar
• Lamoureux F, Duflot T, Woillard JB, et al. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Int J Antimicrob Agents. 2016 Feb;47(2):124–131.
   Google Scholar
• Wang G, Lei HP, Li Z, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009 Mar;65(3):281–285.
   Google Scholar
• Matsumoto K, Ikawa K, Abematsu K, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents. 2009 Jul;34(1):91–94.
   Google Scholar
• Wang T, Zhu H, Sun J, et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents. 2014 Nov;44(5):436–442.
   Google Scholar
• Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis. 2012 Oct;55(8):1080–1087.
   Google Scholar
• Luong ML, Al-Dabbagh M, Groll AH, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 2016 Jul;71(7):1786–1799.
   Google Scholar
• Hoy Z, Dodds Ashley ES, Weinberg GA, et al. Voriconazole therapeutic drug monitoring. J Pediatric Infect Dis Soc. 2014 Sep;3(3):270–271.
   Google Scholar
• Moriyama B, Kadri S, Henning SA, et al. Therapeutic drug monitoring and genotypic screening in the clinical use of voriconazole. Curr Fungal Infect Rep. 2015 Jun;9(2):74–87.
   Google Scholar
• Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010 Oct;54(10):4116–4123.
   Google Scholar
• Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004 Jun;48(6):2166–2172.
   Google Scholar
• Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck; 2019.
   Google Scholar
• Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958–966. Mar.
   Google Scholar
• van der Elst KC, Brouwers CH, van Den Heuvel ER, et al. Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease. Ther Drug Monit. 2015 Dec;37(6):766–771.
   Google Scholar
• Dolton MJ, Bruggemann RJ, Burger DM, et al. Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. Antimicrob Agents Chemother. 2014 Nov;58(11):6879–6885.
   Google Scholar
• Cojutti P, Candoni A, Simeone E, et al. Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. Antimicrob Agents Chemother. 2013 Dec;57(12):6081–6084.
   Google Scholar
• Alffenaar JW, van Assen S, van der Werf TS, et al. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis. 2009 Mar 15;48(6):839.
   Google Scholar
• Dekkers BGJ, Bakker M, KCM VDE, et al. Therapeutic drug monitoring of posaconazole: an update. Curr Fungal Infect Rep. 2016;10:51–61.
   Google Scholar
• Kraft WK, Chang PS, van Iersel ML, et al. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014 Jul;58(7):4020–4025.
   Google Scholar
• Krishna G, Ma L, Martinho M, et al. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012 Aug;56(8):4196–4201.
   Google Scholar
• Kersemaekers WM, Dogterom P, Xu J, et al. Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation. Antimicrob Agents Chemother. 2015;59(6):3385–3389.
   Google Scholar
• Dolton MJ, Ray JE, Marriott D, et al. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother. 2012 Jun;56(6):2806–2813.
   Google Scholar
• Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007 Jan 1;44(1):2–12.
   Google Scholar
• Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006 Jan;50(1):126–133.
   Google Scholar
• Andes D. Optimizing antifungal choice and administration. Curr Med Res Opin. 2013 Apr;29(Suppl 4): 13–18.
   Google Scholar
• Cornely OA, Duarte RF, Haider S, et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother. 2016 Mar;71(3):718–726.
   Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007 Jan 25;356(4):348–359.
   Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007 Jan 25;356(4):335–347.
   Google Scholar
• Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther. 2010 Jul;88(1): 115–119.
   Google Scholar
• Mellinghoff SC, Panse J, Alakel N, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018 Feb;97(2):197–207.
   Google Scholar
• Ostrosky-Zeichner L, Marr KA, Rex JH, et al. Amphotericin B: time for a new “gold standard”. Clin Infect Dis. 2003 Aug 1;37(3):415–425.
   Google Scholar
• Walsh TJ, Lewis RE, Adler-Moore J. Pharmacology of Liposomal Amphotericin B: an introduction to preclinical and clinical advances for treatment of life-threatening invasive fungal infections. Clinl Infect Dis. 2019;68(Supplement_4):S241–S243.
   Google Scholar
• Seibel NL, Shad AT, Bekersky I, et al. Safety, tolerability, and pharmacokinetics of liposomal amphotericin b in immunocompromised pediatric patients. Antimicrob Agents Chemother. 2017 Feb;61(2).
   Google Scholar
• Stone NR, Bicanic T, Salim R, et al. Liposomal Amphotericin B (AmBisome((R))): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs. 2016 Mar;76(4):485–500.
   Google Scholar
• Bellmann R, Egger P, Wiedermann CJ. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence. Clin Infect Dis. 2003 Jun 1;36(11): 1500–1501.
   Google Scholar
• Bekersky I, Fielding RM, Dressler DE, et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002 Mar;46(3):828–833.
   Google Scholar
• Heinemann V, Bosse D, Jehn U, et al. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrob Agents Chemother. 1997 Jun;41(6):1275–1280.
   Google Scholar
• Lestner JM, Groll AH, Aljayyoussi G, et al. Population pharmacokinetics of Liposomal Amphotericin B in immunocompromised children. Antimicrob Agents Chemother. 2016 Dec;60(12):7340–7346.
   Google Scholar
• Fluconazole [package insert]. New York, NY: Roerig Division of Pfizer, Inc.; 2019.
   Google Scholar
• Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011 Aug;86(8): 805–817.
   Google Scholar
• Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007 Jan;51(1): 35–39.
   Google Scholar
• Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006 Apr;19(2): 435–447.
   Google Scholar
• Clancy CJ, Yu VL, Morris AJ, et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother. 2005 Aug;49(8):3171–3177.
   Google Scholar
• Lee JW, Seibel NL, Amantea M, et al. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr. 1992 Jun;120(6):987–993.
   Google Scholar
• Isavuconazole [package insert] Northbrook, IL: Astellas Pharma US, Inc.; 2018.
   Google Scholar
• Andes D, Kovanda L, Desai A, et al. Isavuconazole concentration in real-world practice: consistency with results from clinical trials. Antimicrob Agents Chemother. 2018 Jul;62(7).
   Google Scholar
• A FH A, Steinbach W, Muller W, et al., editor. An open-label, phase I, multicenter study to evaluate the pharmacokinetic, safety, and tolerability profile of intravenous isavuconazonium sulfate in pediatric patients: TOPSPIN (PART 1) Europ Congress for Clin Microbiol Infect Dis (ECCMID). 2019.
   Google Scholar
• Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011 Jan 1;71(1): 11–41.
   Google Scholar
• Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis. 2006;42(8): 1171–1178. Apr 15.
   Google Scholar
• Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother. 1999;43(9):2148–2155. Sep.
   Google Scholar
• JA S, SD H, PJ W, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother. 2002;46(3):739–745. Mar.
   Google Scholar
• Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis. 2004 Nov;23(11): 805–812.
   Google Scholar
• Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit. 2008 Apr;30(2): 167–172.
   Google Scholar
• Louie A, Deziel M, Liu W, et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother. 2005 Dec;49(12):5058–5068.
   Google Scholar
• Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10): 1647–1657.
   Google Scholar
• Benjamin DK Jr., Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. 2006 Feb;50(2):632–638.
   Google Scholar
• Benjamin DK Jr., Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010 Jan;87(1):93–99.
   Google Scholar
• Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005 Aug;49(8):3317–3324.
   Google Scholar
• Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005 Nov;49(11):4536–4545.
   Google Scholar
• Hope WW, Warn PA, Sharp A, et al. Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect. Antimicrob Agents Chemother. 2006 Nov;50(11):3680–3688.
   Google Scholar
• Andes D, van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother. 2000 Apr;44(4): 938–942.
   Google Scholar
• Normark S, Schonebeck J. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata. Antimicrob Agents Chemother. 1972 Sep;2(3): 114–121.
   Google Scholar
• Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010 Feb 1;50(3):291–322.
   Google Scholar
• Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32(Suppl 1):67–87.
   Google Scholar
• Law D, CB M, Denning DW. Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Antimicrob Agents Chemother. 1994 Jul;38(7): 1561–1566.
   Google Scholar
• Wiederhold NP, Pennick GJ, Dorsey SA, et al. A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid. Antimicrob Agents Chemother. 2014;58(1):424–431.
   Google Scholar
• Odds FC, Bossche HV. Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. J Antimicrob Chemother. 2000 Mar;45(3): 371–373.
   Google Scholar
• Odds FC, Dupont B, Rinaldi MG, et al. Bioassays for itraconazole blood levels: an interlaboratory collaborative study. J Antimicrob Chemother. 1999 May;43(5):723–727.
   Google Scholar
• Hostetler JS, Heykants J, Clemons KV, et al. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother. 1993 Oct;37(10):2224–2227..
   Google Scholar
• Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2008 Jun 15;46(12):1801–1812.
   Google Scholar
• Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007 Oct 1;45(7):807–825.
   Google Scholar
• Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018 May;24(Suppl 1):e1–e38.
   Google Scholar
• Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet. 1998 Dec;35(6): 461–473.
   Google Scholar
• Zhang J, Liu Y, Nie X, et al. Trough concentration of itraconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. Infect Drug Resist. 2018;11:1283–1297.
   Google Scholar
• Tricot G, Joosten E, Boogaerts MA, et al. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis. 1987 Jan-Feb;9(Suppl 1):S94–9.
   Google Scholar
• Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses. 1999;42(7–8):443–451.
   Google Scholar
• DW D, JY L, JS H, et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 1994 Aug;97(2):135–144.
   Google Scholar
• RM T, DW D, EG A, et al. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol. 1990 Sep;23(3 Pt 2):593–601.
   Google Scholar
• Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med. 1995 Apr;98(4):336–342.
   Google Scholar
• Chau MM, Kong DC, van Hal SJ, et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Intern Med J. 2014 Dec;44(12b):1364–88.
   Google Scholar
• Laverdiere M, Bow EJ, Rotstein C, et al. Therapeutic drug monitoring for triazoles: a needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol. 2014 Nov-Dec;25(6):327–343.
   Google Scholar
• Baxter CG, Marshall A, Roberts M, et al. Peripheral neuropathy in patients on long-term triazole antifungal therapy. J Antimicrob Chemother. 2011 Sep;66(9):2136–2139.
   Google Scholar
• Lionakis MS, Samonis G, Kontoyiannis DP. Endocrine and metabolic manifestations of invasive fungal infections and systemic antifungal treatment. Mayo Clin Proc. 2008 Sep;83(9): 1046–1060.
   Google Scholar
• Lestner JM, Roberts SA, Moore CB, et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis. 2009 Sep 15;49(6):928–930.
   Google Scholar
• Reynes J, Bazin C, Ajana F, et al. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob Agents Chemother. 1997 Nov;41(11):2554–2558.
   Google Scholar
• Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother. 1988 Sep;32(9):1310–1313.
   Google Scholar
• Bruggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit. 2008 Aug;30(4):403–411.
   Google Scholar
• Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother. 2011 Oct;55(10): 4782–4788.
   Google Scholar
• Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother. 2003 Oct;47(10):3165–3169.
   Google Scholar
• Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008 Jan 15;46(2):201–211. .
   Google Scholar
• Wang T, Xie J, Wang Y, et al. Pharmacokinetic and pharmacodynamic properties of oral voriconazole in patients with invasive fungal infections. Pharmacotherapy. 2015 Sep;35(9):797–804.
   Google Scholar
• Karthaus M, Lehrnbecher T, Lipp HP, et al. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients – an evidence-based approach. Ann Hematol. 2015 Apr;94(4):547–556.
   Google Scholar
• Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther. 2017 Jul;102(1):45–51.
   Google Scholar
• Peman J, Salavert M, Canton E, et al. Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Manag. 2006 Jun;2(2):129–158.
   Google Scholar
• Zonios DI, Gea-Banacloche J, Childs R, et al. Hallucinations during voriconazole therapy. Clin Infect Dis. 2008 Jul 1;47(1):e7–e10.
   Google Scholar
• Hamada Y, Tokimatsu I, Mikamo H, et al. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013 Jun;19(3):381–392.
   Google Scholar
• Perreault S, McManus D, Anderson A, et al. Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies. J Oncol Pharm Pract. 2018 Jan 1:1078155218786028.
   Google Scholar
• Boast A, Curtis N, Cranswick N, et al. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre. J Antimicrob Chemother. 2016;71(7):2031–2036. Jul.
   Google Scholar
• Choi SH, Lee SY, Hwang JY, et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood Cancer. 2013 Jan;60(1):82–87.
   Google Scholar
• Kang HM, Lee HJ, Cho EY, et al. The clinical significance of voriconazole therapeutic drug monitoring in children with invasive fungal infections. Pediatr Hematol Oncol. 2015;32(8):557–567.
   Google Scholar
• Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010 Jan 1;50(1):27–36.
   Google Scholar
• Friberg LE, Ravva P, Karlsson MO, et al. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother. 2012 Jun;56(6):3032–3042.
   Google Scholar
• Shields RK, Clancy CJ, Vadnerkar A, et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother. 2011 Mar;55(3):1308–1311.
   Google Scholar
• Hoenigl M, Raggam RB, Salzer HJ, et al. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents. 2012 Jun;39(6):510–513.
   Google Scholar
• Lebeaux D, Lanternier F, Elie C, et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother. 2009 Dec;53(12):5224–5229.
   Google Scholar
• Seyedmousavi S, Mouton JW, Verweij PE, et al. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev Anti Infect Ther. 2013 Sep;11(9): 931–941.
   Google Scholar
• LiverTox [cited 2019 May 28]. Available from: http://livertox.nlm.nih.gov
   Google Scholar
• Martinez-Casanova J, Carballo N, Luque S, et al. Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis. Infect Drug Resist. 2018;11:317–321.
   Google Scholar
• Park WB, Cho JY, Park SI, et al. Effectiveness of increasing the frequency of posaconazole syrup administration to achieve optimal plasma concentrations in patients with haematological malignancy. Int J Antimicrob Agents. 2016 Jul;48(1):106–110.
   Google Scholar
• Hummert SE, Green MR. Therapeutic drug monitoring and dose adjustment of posaconazole oral suspension in adults with acute myeloid leukemia. Ther Drug Monit. 2015 Aug;37(4): 508–511.
   Google Scholar
• Jung DS, Tverdek FP, Kontoyiannis DP. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother. 2014 Nov;58(11): 6993–6995.
   Google Scholar
• Chin A, Pergam SA, Fredricks DN, et al. Evaluation of posaconazole serum concentrations from delayed-release tablets in patients at high risk for fungal infections. Antimicrob Agents Chemother. 2017 Oct;61(10).
   Google Scholar
• Pham AN, Bubalo JS, Lewis JS 2nd. Posaconazole tablet formulation at 400 milligrams daily achieves desired minimum serum concentrations in adult patients with a hematologic malignancy or stem cell transplant. Antimicrob Agents Chemother. 2016 Nov;60(11): 6945–6947.
   Google Scholar
• Arrieta AC, Sung L, Bradley JS, et al. A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia. PLoS One. 2019;14(3):e0212837.
   Google Scholar
• van der Elst KC, Span LF, van Hateren K, et al. Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. Antimicrob Agents Chemother. 2013 Oct;57(10):4999–5004.
   Google Scholar
• Reddy TM, Tama CI, Hayes RN. A dried blood spots technique based LC-MS/MS method for the analysis of posaconazole in human whole blood samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Nov 15;879(30): 3626–3638.
   Google Scholar
• Lionakis MS, Lewis RE, Kontoyiannis DP. Breakthrough invasive mold infections in the hematology patient: current concepts and future directions. Clin Infect Dis. 2018 Oct 30;67(10): 1621–1630.
   Google Scholar
• Rausch CR, DiPippo AJ, Bose P, et al. Breakthrough fungal infections in patients with leukemia receiving isavuconazole. Clin Infect Dis. 2018 Oct 30;67(10): 1610–1613.
   Google Scholar
• Lempers VL, Bruggemann RJ. Antifungal therapy: drug–drug interactions at your fingertips. J Antimicrob Chemother. 2016;71(2):285–289.
   Google Scholar
• Scorzoni L, ESAC DP, Marcos CM, et al. Antifungal therapy: new advances in the understanding and treatment of mycosis. Front Microbiol. 2017;8:36.
   Google Scholar
• Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2017 Sep;16(9): 603–616.
   Google Scholar
• McCarthy MW, Kontoyiannis DP, Cornely OA, et al. Novel agents and drug targets to meet the challenges of resistant fungi. J Infect Dis. 2017 Aug 15;216(suppl_3):S474–S483.
   Google Scholar
• Yang Z, Liu M, Chen J, et al. Development and characterization of amphotericin B nanosuspensions for oral administration through a simple top-down method. Curr Pharm Biotechnol. 2014;15(6):569–576.
   Google Scholar
• Ickowicz DE, Farber S, Sionov E, et al. Activity, reduced toxicity, and scale-up synthesis of amphotericin B-conjugated polysaccharide. Biomacromolecules. 2014 Jun 9;15(6):2079–2089.
   Google Scholar
• DB MR, Teae A Oral administration of Amphotericin B (CAmB) in humans: a phase I study of tolerability and pharmacokinetics preliminary pharmacokinetics 2019 [cited 2019 June 17]. Available from: https://content.equisolve.net/_db6027646f523d19fe795801a0b7aff1/matinasbiopharma/db/128/510/pdf/Oral_Dosing_of_Encochleated_Amphotericin_B_%28CAmB%29__Rapid_Drug_Targeting_to_Infected_Tissues_in_Mice_with_Invasive_Candidiasis.pdf
   Google Scholar
• Ibrexafungerp (formerly SCY-078): an innovative antifungal.Jersey City, NJ,2019 [cited 2019 May 29]. Available from: https://www.scynexis.com/pipeline.
   Google Scholar
• Cornely OA, Ostrosky-Zeichner L, Spec MR, et al. Favorable response to oral ibrexafungerp (formerly SCY-078) in patients with refractory fungal diseases, interim analysis by pathogen from a phase 3 open-label study (FURI) Europ Congress for Clin Microbiol Infect Dis (ECCMID). Amsterdam, Netherlands. 2019.
   Google Scholar
• Sofjan AK, Mitchell A, Shah DN, et al. Rezafungin (CD101), a next-generation echinocandin: a systematic literature review and assessment of possible place in therapy. J Glob Antimicrob Resist. 2018;14:58–64, Sep
   Google Scholar
• Rezafungin (CD101 IV) overview. San Diego, CA; 2019 [cited 2019 May 29]. Available from: https://www.cidara.com/rezafungin/
   Google Scholar
• Oliver JD, Sibley GEM, Beckmann N, et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12809–12814. .
   Google Scholar
• Shahid SK. Newer patents in antimycotic therapy. Pharm Pat Anal. 2016;5(2):115–134.
   Google Scholar
• Gebremariam T, Alkhazraji S, Alqarihi A, et al. APX001 is effective in the treatment of murine invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2019 Feb;63(2).
   Google Scholar
• Spellberg B. Vaccines for invasive fungal infections. F1000 Med Rep. 2011;3:13.
   Google Scholar
• Edwards JE Jr., Schwartz MM, Schmidt CS, et al. A fungal immunotherapeutic vaccine (NDV-3A) for treatment of recurrent vulvovaginal candidiasis – a phase 2 randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2018 Jun 1;66(12):1928–1936.
   Google Scholar
• Alqarihi A, Singh S, Edwards JE, et al. NDV-3A vaccination protects mice from Candida albicans biofilm infection. bioRxiv. 2018;471771.
   Google Scholar
• Sandison T, Ong V, Lee J, et al. Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother. 2017 Feb;61(2).
   Google Scholar
• SA W, Randolph R, Park S, et al. Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis. Antimicrob Agents Chemother. 2017 Apr;61(4).
   Google Scholar
• Hope WW, McEntee L, Livermore J, et al. Pharmacodynamics of the orotomides against aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease. MBio. 2017 Aug 22;8(4).
   Google Scholar
• Shaw KJ, Schell WA, Covel J, et al. In vitro and in vivo evaluation of APX001A/APX001 and other Gwt1 inhibitors against cryptococcus. Antimicrob Agents Chemother. 2018 Aug;62(8).
   Google Scholar